Machine learning-based detection of Parkinson's disease from facial expressions, hand movements, speech, and gait with general-purpose equipment: a systematic review.

Int J Med InformJul 5, 2026 (epub)
Clinical ResearchNeurology

Anastasiia A Moshkova, Anastasia O Novikova, Maksim I Polguev et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated machine learning (ML) methods for detecting Parkinson's disease (PD) using facial expressions, hand movements, speech, and gait with low-cost equipment. Analyzing 133 studies, it found that speech and voice modalities showed promising trends for classification. Multimodal data fusion improved performance in 75% of studies, although statistical validation was limited.

Key findings

  • 74.5% of studies focused on binary classification tasks for PD detection.
  • Support Vector Machines (SVM) and Random Forests (RF) were the most commonly used classifiers.
  • 75% of studies indicated improved performance with multimodal data fusion.

Why it matters

The integration of machine learning with accessible technology could enhance the objectivity and scalability of Parkinson's disease screening and monitoring, potentially leading to earlier diagnosis and better patient management.

Source

Published in Int J Med Inform. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.